• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    PD-L1 testing and immunotherapy selection - early laboratory experience and its potential role in head and neck cancer management

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    34754934.pdf
    Size:
    489.0Kb
    Format:
    PDF
    Description:
    From UNPAYWALL
    Download
    Authors
    Bancu, A.
    Cowan, Richard A
    Chaturvedi, Anshuman
    Affiliation
    Department of Histopathology and Molecular Pathology, St James's University Hospital, Leeds, UK
    Issue Date
    2021
    
    Metadata
    Show full item record
    Abstract
    Anti-programmed cell death protein-1 (PD-1) therapy has been relatively recently approved in a defined context by NICE in adults in the management of recurrent and metastatic head and neck squamous cell carcinomas (HNSCC). In this context, companion diagnostic programmed cell death ligand-1 (PD-L1) testing, previously established at our center for lung and bladder tumors, was undertaken in a few head and neck cancer cases. The scope of this study was to audit the relevant PD-L1 data and integrate the findings in our current clinical practice, with a view to promote improved routine laboratory biomarkers in HNSCC. Histopathology reports documenting tumor type, PD-L1 result and type of clone/assay were included in this study. Over a 5-year period, PD-L1 testing was undertaken in 199 cancer cases, including 3 with head and neck squamous carcinoma with low focal positive staining. Immunotherapy treatment in HNSCC demonstrates a discreet but still significant improvement in the overall survival of PD-L1 positive subjects.
    Citation
    Bancu B, Cowan R, Chaturvedi A. PD-L1 TESTING AND IMMUNOTHERAPY SELECTION – EARLY LABORATORY EXPERIENCE AND ITS POTENTIAL ROLE IN HEAD AND NECK CANCER MANAGEMENT [Internet]. Vol. 8, Archive of Clinical Cases. Grigore T. Popa University of Medicine and Pharmacy; 2021. p. 14–8.
    Journal
    Archive of Clinical Cases
    URI
    http://hdl.handle.net/10541/624781
    DOI
    10.22551/2021.30.0801.10179
    PubMed ID
    34754934
    Additional Links
    https://dx.doi.org/10.22551/2021.30.0801.10179
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.22551/2021.30.0801.10179
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    • Authors: Rebelatto MC, Midha A, Mistry A, Sabalos C, Schechter N, Li X, Jin X, Steele KE, Robbins PB, Blake-Haskins JA, Walker J
    • Issue date: 2016 Oct 8
    • Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
    • Authors: Xu Y, Zhu G, Maroun CA, Wu IXY, Huang D, Seiwert TY, Liu Y, Mandal R, Zhang X
    • Issue date: 2021
    • The genetic landscape of programmed death ligand-1 (PD-L1) alterations in head and neck cancer.
    • Authors: Heineman TE, Widman A, Kuan EC, St John M
    • Issue date: 2017 Jun
    • Immunohistochemical study of Programmed Cell Death Ligand 1 (PDL1) expression by combined positive score using 22C3 clone in head and neck squamous cell carcinomas, its correlation with clinicopathological features and outcome.
    • Authors: Gangadhar P, Ilanthodi S, Shetty R, Shenoy KK, Philipose TR
    • Issue date: 2024 Jan-Mar
    • PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
    • Authors: Hirata-Nozaki Y, Ohkuri T, Ohara K, Kumai T, Nagata M, Harabuchi S, Kosaka A, Nagato T, Ishibashi K, Oikawa K, Aoki N, Ohara M, Harabuchi Y, Uno Y, Takei H, Celis E, Kobayashi H
    • Issue date: 2019 Jun 20
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.